Bayer's Leadership Prepares For First Innovative Drug Launch In China Ahead Of U.S.

This article was originally published in PharmAsia News

11 Sep 2009
News

PharmAsia News @PharmAsiaNews pharmasia@informa.com

Executive Summary

BEIJING - After obtaining regulatory approval for an innovative new anticoagulant in Beijing while a simultaneously filed application is still being reviewed by the U.S. FDA in Washington, DC, the leadership of Bayer Schering Pharma AG is now crafting a plan for the release of the drug in China ahead of the United States

Already Registered? Sign in to continue reading.

New to Scrip? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

SC072726

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

SC072726

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Bayer's Leadership Prepares For First Innovative Drug Launch In China Ahead Of U.S.

News

Executive Summary

Related Content

Bayer Taps Pfizer Emerging Markets Head To Lead Health Care Division

Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So

Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So

China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome

China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome

Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population

Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert